search buttonmobile navigation expand button

Need Assistance?

Back to Search Results


S1207, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of  Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy."
The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without cancer returning. The current standard treatment after chemotherapy is hormone treatment alone. Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney or breast cancer. It is considered investigational for non-metastatic breast cancer patients. In this study participants will get hormone treatment with either everolimus or with placebo (a pill with no medication). The combination of hormone-treatment and everolimus is experimental in patients with breast cancer.
Trial Information
Principal Investigator: Dr. Mohammad Chisti, MD

Contact: McLaren Center for Research & Innovation: (248) 484-4960

IRB Number: 2013-00049 01674140

More Information: